- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1750-1172
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Do investors value the FDA orphan drug designation? ; volume:12 ; number:1 ; day:19 ; month:6 ; year:2017 ; pages:1-6 ; date:12.2017
Orphanet journal of rare diseases ; 12, Heft 1 (19.6.2017), 1-6, 12.2017
- Schlagwort
-
Arzneimittelentwicklung
Arzneimitteldesign
- Urheber
-
Miller, Kathleen L.
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s13023-017-0665-6
- URN
-
urn:nbn:de:1111-201709105841
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:25 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Miller, Kathleen L.
- SpringerLink (Online service)
Ähnliche Objekte (12)
The drug development pipeline for glioblastoma: a cross sectional assessment of the FDA orphan drug product designation database
Health technology assessment: oncology drugs with orphan designation as an example
FDA
FDA
FDA
FDA
FDA orphan products clinical trial grants: assessment of outcomes and impact on rare disease product development
Special FDA designations for drug development: orphan, fast track, accelerated approval, priority review, and breakthrough therapy
Evolving prevalence of haematological malignancies in orphan designation procedures in the European Union
Use of biomarkers in the context of orphan medicines designation in the European Union
Establishing medical plausibility in the context of orphan medicines designation in the European Union
The Orphan
The drug development pipeline for glioblastoma: a cross sectional assessment of the FDA orphan drug product designation database
Health technology assessment: oncology drugs with orphan designation as an example
FDA
FDA
FDA
FDA
FDA orphan products clinical trial grants: assessment of outcomes and impact on rare disease product development
Special FDA designations for drug development: orphan, fast track, accelerated approval, priority review, and breakthrough therapy
Evolving prevalence of haematological malignancies in orphan designation procedures in the European Union
Use of biomarkers in the context of orphan medicines designation in the European Union
Establishing medical plausibility in the context of orphan medicines designation in the European Union
The Orphan
The drug development pipeline for glioblastoma: a cross sectional assessment of the FDA orphan drug product designation database
Health technology assessment: oncology drugs with orphan designation as an example
FDA
FDA
FDA
FDA
FDA orphan products clinical trial grants: assessment of outcomes and impact on rare disease product development
Special FDA designations for drug development: orphan, fast track, accelerated approval, priority review, and breakthrough therapy
Evolving prevalence of haematological malignancies in orphan designation procedures in the European Union
Use of biomarkers in the context of orphan medicines designation in the European Union
Establishing medical plausibility in the context of orphan medicines designation in the European Union